CompletedNCT00380692
Atomoxetine for ADHD symptoms in children with autism
About this title
Read the official source — NCT00380692Researchers compared atomoxetine and placebo to find out how the approaches affected ADHD symptoms in children and adolescents with ADHD.
Medication studyAges 6–17Netherlands
Understand this study
What did researchers investigate?
Researchers compared atomoxetine and placebo to find out how the approaches affected ADHD symptoms in children and adolescents with ADHD.
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- Amsterdam and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 97
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Netherlands
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00380692
- Official title
Show the full official title
A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Amsterdam · Groningen · Hoorn
5 more locations
- Maastricht
- Nijmegen
- Oosterhout
- The Hague
- Utrecht
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared atomoxetine and placebo to find out how the approaches affected ADHD symptoms in children and adolescents with ADHD.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine and Placebo.
Who was this study for?
Listed age limits: 6 years to 17 years.
Want to explore more studies?
Explore studiesRelated studies
Atomoxetine or placebo to maintain response in adult ADHD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...